TABLE 3.

Ongoing clinical trials targeting inflammation.

Drug	Trial identifier	Disease	Primary endpoint	Duration of therapy	Phase and status	Sponsor
Anakinra (interleukin 1 blockade)	NCT03797001	Heart failure, systolic, inflammation	Changes in peak VO2 at earlier endpoints	24 Weeks	Phase 2; recruiting	Virginia Commonwealth University
Proleukin (interleukin 2)	NCT03113773	Ischemic heart disease	–	5 Days	Phase 1/2; active, not recruiting	Cambridge University Hospitals NHS Foundation Trust
Interleukin 2 (IL-2)	NCT04241601	Acute coronary syndromes	Change in vascular inflammation	5 Days	Phase 2; recruiting	Cambridge University Hospitals NHS Foundation Trust
Colchicine (anti-inflammatory)	NCT04857931	Heart failure, inflammation	Change in hs-CRP (C-reactive protein)	–	Phase 3; not yet recruiting	Montreal Heart Institute
Colchicine (anti-inflammatory)	NCT04420624	Myocardial infarction, acute	Percentage of myocardial denervation	1 Month	Phase 2/3; recruiting	University Hospital, Montpellier